From the data presented, it would appear that PiZ subjects who develop clinically significant airflow limitation go through a phase of their disease in which there is a relatively high rate of functional decline. This is encouraging in regard to the feasibility of a trial of antiprotease therapy. It suggests that beneficial effects of such therapy could be demonstrated by showing a reduction in the rate of loss of function in subjects properly selected for such a clinical trial.
|Original language||English (US)|
|Journal||American Review of Respiratory Disease|
|State||Published - Jul 7 1983|
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine